Triazine-Carbosilane Dendrimersomes for Anticancer Photodynamic Therapy

Triazine-carbosilane dendrimersomes are promising drug carriers for anticancer photodynamic therapy (PDT), according to a recent report published in the International Journal of Nanomedicine.

Researchers aimed to report the assembly of triazine-carbosilane dendron-based dendrimersomes loaded with rose bengal (RB) and proof of concept studies of their efficacy in PDT. Dendrons were synthesized using an established protocol and analytical and spectroscopy techniques. The nanosystem was confirmed with biophysical methods.

Cellular uptake, intracellular reactive oxygen species (ROS) production, and the phototoxicity of the photosensitizer (PS) are enhanced with encapsulation of RB inside basal cell carcinoma cell lines.

“Our findings suggest that dendrimersomes built of amphiphilic triazine-carbosilane dendrons are robust vehicles for delivering RB into basal skin cancer cells, increasing the therapeutic performance of the PS through increased cellular uptake and intracellular ROS generation,” concluded the study authors.

Reference
Sztandera K, Gorzkiewicz M, Bątal M, et al. Triazine-carbosilane dendrimersomes enhance cellular uptake and phototoxic activity of rose bengal in basal cell skin carcinoma cells. Int J Nanomedicine. Published online March 15, 2022. doi:10.2147/IJN.S352349